Sort   by:  
 Page size 
UnknownSmoking status during first-line immunotherapy and chemotherapy in NSCLC patients: A case-control matched analysis from a large multicenter study.
Not available
S-EPMC7952794 | biostudies-literature
UnknownThe lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer.
Not available
S-EPMC7988288 | biostudies-literature
UnknownHigh familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status.
Not available
S-EPMC8780322 | biostudies-literature
UnknownTocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial.
Not available
S-EPMC7576974 | biostudies-literature
Sort   by:  
 Page size